Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSg· March 30, 2026

Dollar holds firm as risk of protracted Middle East war saps sentiment

View original at sg.finance.yahoo.com
Dollar holds firm as risk of protracted Middle East war saps sentiment By Ankur Banerjee SINGAPORE, March 30 (Reuters) - The U.S…
Opening lines of the source · Sg · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Only two weeks ago, U.S. boots on the ground in Iran was seen as a low-probability outcome, but that has clearly changed

    60% confidence

  • Bank of Japan is watching exchange-rate moves closely and recognizes their powerful impact on growth and inflation

    60% confidence

  • Iran is ready to respond if the United States launches a ground operation

    60% confidence

  • In this environment, traders remain defensive with the playbook being to sell rallies in risk and maintain volatility hedges

    60% confidence

  • Japanese authorities stand ready to take decisive steps if speculative moves continue in the foreign exchange market

    60% confidence

  • A direct market intervention will rapidly pull USD/JPY down by a few yen

    60% confidence

  • Pakistan is preparing to host meaningful talks to end the Middle East conflict in coming days

    60% confidence

  • Recent weakening of the JPY is driven by fundamentals rather than speculation

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Dollar holds firm as risk of protracted Middle East war saps sentiment — Source | Via News | ViaNews EU